scholarly article | Q13442814 |
P50 | author | Fan Li | Q57036756 |
P2093 | author name string | Andrew J Vickers | |
Ying Wang | |||
Keith A Baggerly | |||
Andrew S Allen | |||
Melissa J Assel | |||
P2860 | cites work | A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 | Q24544001 |
No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 | Q34620551 | ||
Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test? | Q34778837 | ||
A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer | Q38278153 | ||
CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration | Q43953153 | ||
Author reply: To PMID 24974817. | Q44581716 | ||
Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study | Q44915960 | ||
Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis. | Q51608120 | ||
CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration | Q81117261 | ||
Re: Chew et al.: No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 (Ophthalmology 2014;121:2173-80) | Q85650478 | ||
Should we test for genotype in deciding on age-related eye disease study supplementation? | Q86411240 | ||
P921 | main subject | statistics | Q12483 |
eye disease | Q3041498 | ||
macular degeneration | Q27429789 | ||
P577 | publication date | 2017-10-09 | |
P1433 | published in | Ophthalmology | Q7098109 |
P1476 | title | Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration: Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study |
Q47567166 | CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation |
Q52559837 | Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration. |
Q93102835 | Nutrients for Prevention of Macular Degeneration and Eye-Related Diseases |
Q64956915 | Pharmacogenomics of antioxidant supplementation to prevent age-related macular degeneration. |
Q64124312 | Reply to Vickers: Pharmacogenetics and progression to neovascular age-related macular degeneration-Evidence supporting practice change |
Q92751432 | Serum 25-Hydroxyvitamin D Concentrations and Incidence of Age-Related Macular Degeneration: The Atherosclerosis Risk in Communities Study |
Search more.